Emerging function of mTORC2 as a core regulator in glioblastoma:metabolic reprogramming and drug res

• 作 者: Si-Han Wu Jun-Feng Bi Timothy
• 机 构: Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093, USA“,
• 出 处: 癌症生物学与医学（英文版）
• 发表日期: 2014年4期
• 关键词: Glioblastoma mTOR metabolic reprogramming mTORC2 Warburg effect PI3K

Glioblastoma (GBM) is one of the most lethal human cancers. Genomic analyses deifne the molecular architecture of GBM and highlight a central function for mechanistic target of rapamycin (mTOR) signaling. mTOR kinase exists in two multi-protein complexes, namely, mTORC1 and mTORC2. hTese complexes differ in terms of function, regulation and rapamycin sensitivity. mTORC1 is well established as a cancer drug target, whereas the functions of mTORC2 in cancer, including GBM, remains poorly understood. hTis study reviews the recent ifndings that demonstrate a central function of mTORC2 in regulating tumor growth, metabolic reprogramming, and targeted therapy resistance in GBM, which makes mTORC2 as a critical GBM drug target.